Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Telix Pharmaceuticals Limited for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The law firm is reaching out to investors who purchased or acquired Telix shares and suffered losses, encouraging them to discuss their legal rights and options [1][2]. - There is no cost or obligation for investors to contact the firm regarding these claims [2]. Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California, representing individual and institutional investors in various complex litigations [3]. - The firm specializes in commercial, securities, and derivative litigation in state and federal courts across the United States [3]. Recent Developments - On July 22, 2025, Telix received a subpoena from the U.S. Securities and Exchange Commission, seeking documents related to the company's disclosures about its prostate cancer therapeutic candidates [5]. - Following this news, Telix's American Depositary Receipt (ADR) price dropped by $1.70, or 10.44%, closing at $14.58 per ADR on July 23, 2025 [5].
TELIX INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Investors to Contact the Firm Regarding Ongoing Investigation on Behalf of Stockholders